SCIEX X500B QTOF High-Resolution Mass Spectrometry System

Overview

The SCIEX X500B QTOF is a high-resolution, accurate-mass quadrupole-time-of-flight mass spectrometer engineered for robust, reproducible characterization of biopharmaceuticals. Operating on the fundamental principle of orthogonal acceleration time-of-flight (oa-TOF) mass analysis coupled with a radiofrequency-only quadrupole collision cell, the system delivers sub-ppm mass accuracy, high mass resolution (>35,000 FWHM at m/z 1,000), and excellent sensitivity across dynamic range—critical for intact protein analysis, peptide mapping, and post-translational modification (PTM) profiling. Designed as an integrated LC-MS platform, it supports both reversed-phase and hydrophilic interaction liquid chromatography (HILIC) separations, enabling comprehensive assessment of monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion proteins, and biosimilars under regulated and research environments.

Key Features

• Quadrupole-TOF architecture with dual-stage mass filtering and high-transmission oa-TOF analyzer for simultaneous high-resolution and high-sensitivity acquisition
• Turbo V™ electrospray ionization (ESI) source optimized for native and denatured protein workflows, delivering enhanced ion transmission and stable signal across variable flow rates (5–1,000 µL/min)
• Mass accuracy 35,000 FWHM at m/z 1,000 in full-scan mode, supporting confident identification and quantitation of structural variants
• Dedicated biopharma acquisition methods—including Intact Mass, Reduced Mass, Peptide Mapping, and DAR (Drug-to-Antibody Ratio) workflows—pre-configured in SCIEX OS software
• Collision-induced dissociation (CID) and electron-transfer/higher-energy collisional dissociation (EThcD) capabilities for deep sequence coverage and PTM localization
• Modular hardware design compatible with UPLC/HPLC systems, nanoLC interfaces, and automated sample introduction platforms

Sample Compatibility & Compliance

The X500B accommodates diverse biopharmaceutical sample formats including reduced and non-reduced mAb preparations, enzymatically digested peptides (e.g., trypsin, Lys-C), glycopeptides, ADC lysates, and intact protein complexes (up to ~150 kDa). It meets key regulatory expectations for analytical method development and validation per ICH Q5E, Q5B, and USP . Data integrity is supported through audit-trail-enabled software compliant with FDA 21 CFR Part 11 requirements when deployed in validated environments. The system adheres to ISO/IEC 17025 principles for testing laboratories and supports GLP/GMP-aligned instrument qualification protocols (IQ/OQ/PQ).

Software & Data Management

SCIEX OS serves as the unified acquisition and control platform, offering intuitive workflow-driven method setup, real-time spectral monitoring, and automated calibration. BioPharmaView™ software provides purpose-built processing modules for intact mass deconvolution, peptide mapping alignment, PTM annotation (including glycosylation, oxidation, deamidation, C-terminal lysine clipping), disulfide bond mapping, and DAR calculation via hydrophobic interaction chromatography (HIC)-MS integration. All processing steps generate traceable, exportable reports with embedded metadata, supporting compliance with ALCOA+ data governance principles. Raw data files (.wiff) are compatible with third-party tools including ProteinPilot™, Byonic™, and Skyline for extended interrogation.

Applications

• Intact and subunit mass analysis for primary structure confirmation and variant detection
• Peptide mapping with ≥95% sequence coverage for identity and purity assessment
• Comprehensive PTM profiling—including site-specific glycosylation heterogeneity, methionine oxidation, asparagine deamidation, and N-/C-terminal modifications
• ADC characterization: DAR distribution quantification, payload attachment site identification, and linker stability evaluation
• Comparability studies across manufacturing lots, process changes, or biosimilar reference comparisons
• Stability-indicating assays tracking degradation pathways during accelerated and real-time storage studies

FAQ

What mass accuracy can be achieved under routine biopharma analysis conditions?

Typical mass accuracy is ≤ 2.5 ppm RMS for calibrated spectra acquired using internal lock mass correction and standard tuning mixtures.
Is the X500B suitable for intact mAb analysis without prior reduction?

Yes—the system supports native and denatured intact mass analysis up to ~150 kDa, with deconvolution algorithms optimized for charge-state distribution resolution and isotopic fidelity.
Does BioPharmaView™ support automated glycoform assignment?

Yes—it includes a built-in glycan library search engine with customizable monosaccharide composition rules and retention time alignment for HILIC-MS glycopeptide data.
Can the system be qualified for GMP-compliant release testing?

Yes—when deployed with documented IQ/OQ/PQ protocols, Part 11-compliant user access controls, and electronic signature workflows, it meets current regulatory expectations for QC release applications.
What LC systems are validated for use with the X500B?

SCIEX provides application notes and method packages for Waters ACQUITY UPLC, Thermo Vanquish, and Agilent 1290 Infinity II systems, including gradient optimization and carryover mitigation strategies.